These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

468 related articles for article (PubMed ID: 24814524)

  • 1. Evaluating the potential risks and benefits of infant rotavirus vaccination in England.
    Clark A; Jit M; Andrews N; Atchison C; Edmunds WJ; Sanderson C
    Vaccine; 2014 Jun; 32(29):3604-10. PubMed ID: 24814524
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Benefit Versus Risk Assessment of Rotavirus Vaccination in France: A Simulation and Modeling Analysis.
    Ledent E; Arlegui H; Buyse H; Basile P; Karkada N; Praet N; Nachbaur G
    BioDrugs; 2018 Apr; 32(2):139-152. PubMed ID: 29589230
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A benefit-risk analysis of rotavirus vaccination, France, 2015.
    Lamrani A; Tubert-Bitter P; Hill C; Escolano S
    Euro Surveill; 2017 Dec; 22(50):. PubMed ID: 29258644
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potential intussusception risk versus health benefits from rotavirus vaccination in Latin America.
    Desai R; Parashar UD; Lopman B; de Oliveira LH; Clark AD; Sanderson CF; Tate JE; Matus CR; Andrus JK; Patel MM
    Clin Infect Dis; 2012 May; 54(10):1397-405. PubMed ID: 22431803
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mortality reduction benefits and intussusception risks of rotavirus vaccination in 135 low-income and middle-income countries: a modelling analysis of current and alternative schedules.
    Clark A; Tate J; Parashar U; Jit M; Hasso-Agopsowicz M; Henschke N; Lopman B; Van Zandvoort K; Pecenka C; Fine P; Sanderson C
    Lancet Glob Health; 2019 Nov; 7(11):e1541-e1552. PubMed ID: 31607466
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Post-Marketing Benefit-Risk Assessment of Rotavirus Vaccination in Japan: A Simulation and Modelling Analysis.
    Ledent E; Lieftucht A; Buyse H; Sugiyama K; Mckenna M; Holl K
    Drug Saf; 2016 Mar; 39(3):219-30. PubMed ID: 26748506
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Update on Rotarix: an oral human rotavirus vaccine.
    O'Ryan M; Linhares AC
    Expert Rev Vaccines; 2009 Dec; 8(12):1627-41. PubMed ID: 19943758
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety of the pentavalent rotavirus vaccine (PRV), RotaTeq(®), in Kenya, including among HIV-infected and HIV-exposed infants.
    Laserson KF; Nyakundi D; Feikin DR; Nyambane G; Cook E; Oyieko J; Ojwando J; Rivers SB; Ciarlet M; Neuzil KM; Breiman RF
    Vaccine; 2012 Apr; 30 Suppl 1():A61-70. PubMed ID: 22520138
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Direct and indirect impact on rotavirus positive and all-cause gastroenteritis hospitalisations in South Australian children following the introduction of rotavirus vaccination.
    Clarke MF; Davidson GP; Gold MS; Marshall HS
    Vaccine; 2011 Jun; 29(29-30):4663-7. PubMed ID: 21575665
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Burden of paediatric rotavirus gastroenteritis and potential benefits of a universal rotavirus vaccination programme with RotaTeq in France.
    Huet F; Largeron N; Trichard M; Miadi-Fargier H; Jasso-Mosqueda G
    Vaccine; 2007 Aug; 25(34):6348-58. PubMed ID: 17629598
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rotavirus infection and intussusception in Tunisian children: implications for use of attenuated rotavirus vaccines.
    Chouikha A; Fodha I; Maazoun K; Ben Brahim M; Hidouri S; Nouri A; Trabelsi A; Steele AD
    J Pediatr Surg; 2009 Nov; 44(11):2133-8. PubMed ID: 19944222
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Broadening the age restriction for initiating rotavirus vaccination in regions with high rotavirus mortality: benefits of mortality reduction versus risk of fatal intussusception.
    Patel MM; Clark AD; Glass RI; Greenberg H; Tate J; Santosham M; Sanderson CF; Steele D; Cortese M; Parashar UD
    Vaccine; 2009 May; 27(22):2916-22. PubMed ID: 19428901
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epidemiology of intussusception before and after rotavirus vaccine introduction in Fiji.
    Ratu FT; Reyburn R; Tuivaga E; Tuiketei A; Jenkins K; Mulholland K; Jenney A; Russell F
    Sci Rep; 2018 Jul; 8(1):11194. PubMed ID: 30046133
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Review of Over 15 Years Postmarketing Safety Surveillance Spontaneous Data for the Human Rotavirus Vaccine (Rotarix) on Intussusception.
    Singh T; Delannois F; Haguinet F; Molo LY
    Drug Saf; 2022 Feb; 45(2):155-168. PubMed ID: 35015268
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Removing the age restrictions for rotavirus vaccination: a benefit-risk modeling analysis.
    Patel MM; Clark AD; Sanderson CF; Tate J; Parashar UD
    PLoS Med; 2012; 9(10):e1001330. PubMed ID: 23109915
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rotavirus vaccines.
    Vesikari T
    Scand J Infect Dis; 2008; 40(9):691-5. PubMed ID: 19086243
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Accounting for indirect protection in the benefit-risk ratio estimation of rotavirus vaccination in children under the age of 5 years, France, 2018.
    Escolano S; Mueller JE; Tubert-Bitter P
    Euro Surveill; 2020 Aug; 25(33):. PubMed ID: 32820718
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intussusception risk and disease prevention associated with rotavirus vaccines in Australia's National Immunization Program.
    Carlin JB; Macartney KK; Lee KJ; Quinn HE; Buttery J; Lopert R; Bines J; McIntyre PB
    Clin Infect Dis; 2013 Nov; 57(10):1427-34. PubMed ID: 23964090
    [TBL] [Abstract][Full Text] [Related]  

  • 19. RotaTeq, a pentavalent rotavirus vaccine: efficacy and safety among infants in Europe.
    Vesikari T; Itzler R; Karvonen A; Korhonen T; Van Damme P; Behre U; Bona G; Gothefors L; Heaton PM; Dallas M; Goveia MG
    Vaccine; 2009 Dec; 28(2):345-51. PubMed ID: 19879226
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incorporation of a rotavirus vaccine into the national immunisation schedule in the United Kingdom: a review.
    Nakagomi O; Iturriza-Gomara M; Nakagomi T; Cunliffe NA
    Expert Opin Biol Ther; 2013 Nov; 13(11):1613-21. PubMed ID: 24088009
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.